🚨Save the date 🚨
ASCO International Medical Graduates Community of Practice Meeting
⏰May 31st, 4-6 PM CST
📌Room S103, McCormick Place
Join us to discuss barriers & opportunities for IMGs in #oncology
ASCO IMG CoP 👉bit.ly/3JmJQwK
ASCOPost #IMG #MedEd #MedTwitter

A few reasons why I’ve been late to see patients:

A child’s cancer relapsed, family devastated

An adolescent expressed suicidal intent

A child with life threatening anaphylaxis

Things that have never been the reason I was late:

Eating bon bons

Not valuing patients time

🎉 Great read for those starting their fellowship soon! Thrilled to have been part of this, a fantastic collaboration with Hem-Onc Fellows Network. Huge shoutout to Karun Neupane, MD for spearheading this project. Stay tuned for more epic collabs coming your way! 🚀

📢 Our article based on two different TwitterSpace sessions on Surviving HemOnc Fellowship is now out on ASCO Connection!

Kudos to the whole team on this impressive coordinated effort🙌👏😃

This is a 💎 for the trainees 💫

connection.asco.org/blogs/survivin…
Manni Mohyuddin

FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. fda.gov/drugs/resource…

#OCENewsBurst

Comprehensive review on the topic lead by 2 brilliant GU ⭐️ Chiara Mercinelli Houssein Safa, MD ⭐️

Our review on novel therapeutic approaches on #PSCC is finally out! It was a pleasure to co-lead this work with Houssein Safa, MD, with the invaluable guidance of jc Philippe spiess & Andrea Necchi
#GUoncology #rarecancer #penilecancer

doi.org/10.1080/146565…

After a wonderful discussion on 'SURVIVING HEM-ONC FELLOWSHIP' last Sunday, we are meeting again this Wednesday (March 20) at 6PM EST for the second part of this discussion!

Dont forget to join us. And bring your questions, it will be an open discussion

Senior academic solid tumor oncologist trying to guess the right answer on the ABIM MOC exam about molar pregnancy and Burkitt lymphoma on a lovely Sunday night…

A huge thanks to our guest speakers Gliceida Galarza, MD & Houssein Safa, MD for their words of wisdom for incoming H/O fellows & host Karun Neupane, MD. Special thanks to Muhammad Salman Faisal & Fernando Diaz, MD for adding to the discussion!

Thanks to our amazing colleagues in the audience!

Join us today at 6pm EST as Karun Neupane, MD hosts Gliceida Galarza, MD & Houssein Safa, MD to discuss about their journeys as Hem-Onc fellows.
It will be an open forum 😃, so bring your questions

If you are a H/O fellow, we would love for you to join the discussion & share your insights.

📢Current/prospective #HemOnc #fellows & #residents considering fellowship, join us (bring your questions⁉️) as we discuss on Surviving Fellowship! Fellows are invited to share their own experiences too.

🎙️Hem-Onc Fellows Network will be hosting 2 sessions:

📅 March 10 & 20 (6-7pm EST)

Printed medical journals have such dismal survival rates, they should be a case study in their own pages. From printer to trash can, faster than you can say “obsolete”. Nostalgia, or just a pricey paperweight tradition? Nothing more screams “innovation” in our digital world!

Doing what you love is overrated
Loving what you do is underrated

🌟Thanks Philippe spiess Moffitt Cancer Center 👑 it took a village to put this important data set together Kyle M Rose writing it w style and the many amazing gobal disease leaders and friends Curtis Pettaway, MD MD Anderson Cancer Center Maarten Albersen Viraj Master Bassel Nazha, MD, MPH JNCI

Privileged, to say the least, to be working with an exceptional mentor and friend jc to get this published. Very excited to see our piece highlighted in ASCO ASCOPost, and looking forward to many more collabs with Mahati Paravathaneni, MD and the team.

Our MCW Cancer Center Razelle Kurzrock, MD UC San Diego Health Daisuke Nishizaki, MD findings: LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not clinical outcomes‼️ High LAG-3 levels do NOT predict resistance to anti-PD-1/PD-L1 checkpoint blockade‼️ bit.ly/486fyIG

🚨‼️Important efforts to summarize the quality and standardization of PRO in GU clinical trials approved by the FDA w important implications on the future of improving value of care ASCO lead by Houssein Safa, MD Mahati Paravathaneni, MD Moffitt Cancer Center Moffitt Urologic Oncology Fellowship Philippe spiess